Enlivex Therapeutics Ltd (ENLV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.72M
Last updated: Nov 17, 2026 at 4:26 PM ET
Enlivex Therapeutics Ltd (ENLV) Stock Chart
Enlivex Therapeutics (ENLV) has a latest price of $1.15 on Nov 17, 2026, 99.6% below its 52-week high of $316.80. Its price fell 99.5% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 59.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $14,584.71 in Oct 2016 and its lowest $1.78 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ENLV with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ENLV.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 95.8%, and over 6 months it fell 99.3%. The month-end price fell 99.4% over the 3 years through Oct 2026, a compound annual decline of 82.3%.
| Period | Change |
|---|---|
| 1 month | -65.3% |
| 3 months | -95.8% |
| 6 months | -99.3% |
| 12 months | -99.5% |
| 12 months, with dividends | -99.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -99.4% | -82.3% |
| 5 years | -99.9% | -75.4% |
| 10 years | -100.0% | -59.4% |
Price by Year
Its best calendar year was 2019, when the price rose 35.5%, and its weakest was 2018, when it fell 66.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.78 | -98.9% |
| 2025 | $168.68 | -39.9% |
| 2024 | $280.66 | -56.7% |
| 2023 | $647.68 | -31.4% |
| 2022 | $944.53 | -37.0% |
| 2021 | $1,499.25 | -25.9% |
| 2020 | $2,022.19 | +0.5% |
| 2019 | $2,012.83 | +35.5% |
| 2018 | $1,484.95 | -66.2% |
| 2017 | $4,386.93 | -56.0% |
Trading Range
The price is 80.0% below its 50-day average of $5.74 and 99.1% below its 200-day average of $124.31.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.15 | |
| 52-week high | $316.80 | -99.6% |
| 52-week low | $1.00 | +15.0% |
| 50-day average | $5.74 | -80.0% |
| 200-day average | $124.31 | -99.1% |
Price Risk
Over 3 years, its largest fall from a peak was 99.9%.
| Measure | Value |
|---|---|
| 1-year beta | 1.71 |
| Largest fall, 1 year | -99.6% |
| Largest fall, 3 years | -99.9% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ENLV
What is ENLV's 1-year price change?
Enlivex Therapeutics's price fell 99.5% over the past 12 months. With dividends included, the 12-month total return was -99.5%.
What is ENLV's 5-year price change?
Enlivex Therapeutics's month-end price fell 99.9% over the 5 years through Oct 2026, a compound annual decline of 75.4%. These figures leave out dividends.
What is ENLV's 52-week high and low?
Enlivex Therapeutics's 52-week high is $316.80 and its 52-week low is $1.00. Its latest price of $1.15 on Nov 17, 2026 is 99.6% below the high.
What is ENLV's beta?
Enlivex Therapeutics's 1-year beta against the S&P 500 is 1.71, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 99.6%.
Is the ENLV chart free?
Yes. Advanced Charting for ENLV is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ENLV pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors